HC Wainwright & Co. Maintains Buy on Insmed, Raises Price Target to $90
Portfolio Pulse from Benzinga Newsdesk
HC Wainwright & Co. has maintained a Buy rating on Insmed (NASDAQ:INSM) and raised the price target from $70 to $90, as per analyst Andrew Fein.
July 08, 2024 | 10:36 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
HC Wainwright & Co. has maintained a Buy rating on Insmed and raised the price target from $70 to $90, indicating strong confidence in the company's future performance.
The raised price target from $70 to $90 by a reputable analyst suggests a positive outlook for Insmed's future performance. This is likely to boost investor confidence and drive the stock price up in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100